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• The horses receive an anti-inflammatory, Phenylbutazone.
• Hoof samples are collected after 28 days.
• Blood samples are collected before injection and before hoof collection for
antibody comparison.
• One horse was injected with a marker gene.
• One horse was injected with a vector mixture of marker genes and TIMP-3
genes.

Lab Tests
The hoof samples will be analyzed using β-Gal staining, quantitative realtime polymerase chain reaction (qPCR), western blot, and
immunochemistry (IHC) tests.
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• Evaluates the distribution of protein expression
• Stains marker proteins red

• Gel electrophoresis
• Evaluates the distribution of transduction
• Detects and quantifies the vector
• Gel electrophoresis chemiluminescence,
radiograph film exposure.
• Detects concentration and occurrence of TIMP-3
proteins in the lamellar tissue samples
• Immunostaining
• Examined for intensity and distribution of the
TIMP-3 protein
• protein localization
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Figure 1: Palpating lateral digital vein for standing regional limb perfusion.
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Currently, there are no effective prevention or treatment strategies for
laminitis. The limited access nature of the deep hoof tissues makes laminitis a
good candidate for gene therapy. This gene therapy study uses a viral vector
(rAAV) to transduce lamellar target cells with a therapeutic gene (TIMP-3
gene). The expression of the TIMP-3 gene will produce the TIMP-3 protein.
Gene therapy using rAAV TIMP-3 should allow the lamellar tissue to resume
homeostasis between aggrecanases and TIMP-3.
Previous studies have determined optimal vectors, promoters, serotypes,
and surfactants for successful transduction and distribution of marker genes.
The in vivo studies administered the vector using lateral Regional Limb
Profusion (RLP) which requires general anesthesia. The current study uses a
standard veterinary technique, standing RLP, in which the horse is only mildly
sedated. This study will apply principles learned from parent studies to deliver
the therapeutic gene TIMP-3 deep into the equine hoof.
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Laminitis is the most common cause of
lameness and the second most common
reason for euthanasia in horses. Though the
onset of laminitis is multifactorial, this
crippling disease is characterized by the
breakdown of the lamina, the separation of
the coffin bone from the hoof wall, and the
eventual downward rotation of the coffin
bone causing extreme pain. The epidermal
and dermal layers of the hoof are stabilized
by connective tissues partly composed of Figure 1: The degradation of
proteoglycans known as aggrecans. In the the lamina causes the
rotation of the distal phalanx.
healthy lamina, a group of proteinases
known as aggrecanases breakdown aggrecan. Tissue Inhibitor of
Metalloproteinases (TIMP-3) inhibit excessive aggrecanase activity. During
laminitis, aggrecanase production is upregulated.
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Figure 2: rAAV copy number assay. We performed qPCR of the
transduced tissue regions (A-I) to detect the number of viral genomes
incorporated into each region of hoof tissue. A) The original injections were
performed with the horse in lateral recumbency under general anesthesia.
B) The current experimental injections were performed using a common
clinical standing regional limb perfusion with the horse sedated.

Conclusions
Because of similar distribution patterns of transduction and expression of
marker rAAV vectors, Standing RLP is an appropriate replacement technique for
lateral RLP. Using standing RLP to deliver the therapeutic vector will allow
veterinarians to administer this treatment using a standard clinical procedure.
If the hoof successfully transduces and expresses the TIMP-3 gene, there will
be sufficient evidence to allow for future studies evaluating the effects of gene
therapy on clinical cases of equine laminitis. This could lead to the first effective
preventative therapy against laminitis.
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